Paul Saladino· MD
in addition to that I would probably add an LP little a for people
Loading…
The evidence is convergent. Multiple independent sources reach the same conclusion, the underlying mechanism is well-characterized, and even the field's most cautious voices treat it as worth doing.
in addition to that I would probably add an LP little a for people
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
and so it's still associated with risk even when the LDL is low and you really need to you know measure it because you know if you think your LDL is low you may be missing some residual risk depending on you know whether leopardy a is making up a significant component of that
so you measure LP little a that's easy and you see it's not a major contributor APO B but it's a terribly atherogenic particle so we get nervous with it
apob is the aggregate marker of uh all of the atherogenic proteins uh because LP little a is so disproportionately atherogenic um you have to look at it separately because even an elevated LP little a won't show up elevating an apob B